David Ladkani

1.2k total citations
27 papers, 868 citations indexed

About

David Ladkani is a scholar working on Pathology and Forensic Medicine, Rheumatology and Neurology. According to data from OpenAlex, David Ladkani has authored 27 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 9 papers in Rheumatology and 7 papers in Neurology. Recurrent topics in David Ladkani's work include Multiple Sclerosis Research Studies (16 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Peripheral Neuropathies and Disorders (6 papers). David Ladkani is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Peripheral Neuropathies and Disorders (6 papers). David Ladkani collaborates with scholars based in Israel, United States and Italy. David Ladkani's co-authors include Jerry S. Wolinsky, Shaul Kadosh, Aaron Miller, Kenneth P. Johnson, Massimo Filippi, Corey C. Ford, Patricia K. Coyle, Ponnada A. Narayana, Paul O’Connor and Marco Rovaris and has published in prestigious journals such as PLoS ONE, Neurology and Annals of Neurology.

In The Last Decade

David Ladkani

27 papers receiving 823 citations

Peers

David Ladkani

PFM

NEURO

RHEUM

IMMUN

ONCOL

Lewis Waber United States

Yanfei Li China

Kimberly Benson United States

Dongdong Lin China

K.G. Kjellin Sweden

I Tobbia Ireland

Zhe Guan China

Kazuo Noguchi Japan

Man Tang Netherlands

Ana Cristina Puga United States

Lewis Waber United States

David Ladkani

101 ×0.2

PFM

42 ×0.1

NEURO

286 ×1.4

RHEUM

25 ×0.1

IMMUN

42 ×0.3

ONCOL

Citations per year, relative to David Ladkani David Ladkani (= 1×) peers Lewis Waber

Countries citing papers authored by David Ladkani

Since Specialization

Citations

This map shows the geographic impact of David Ladkani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ladkani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ladkani more than expected).

Fields of papers citing papers by David Ladkani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ladkani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ladkani. The network helps show where David Ladkani may publish in the future.

Co-authorship network of co-authors of David Ladkani

This figure shows the co-authorship network connecting the top 25 collaborators of David Ladkani. A scholar is included among the top collaborators of David Ladkani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ladkani. David Ladkani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamamura, Takashi, David Ladkani, Toshiyuki Fukazawa, et al.. (2017). Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis. Clinical and Experimental Neuroimmunology. 8(2). 129–137. 3 indexed citations

Grossman, Iris, Volker Knappertz, Daphna Laifenfeld, et al.. (2016). Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Progress in Neurobiology. 152. 114–130. 20 indexed citations

Cutter, Gary, Volker Knappertz, Noah J. Sasson, & David Ladkani. (2016). Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. BMC Neurology. 16(1). 176–176. 2 indexed citations

Kolitz, Sarah, Fadi Towfic, Daphna Laifenfeld, et al.. (2015). Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology. 290. 84–95. 17 indexed citations

Kolitz, Sarah, Fadi Towfic, Jason Funt, et al.. (2015). Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports. 5(1). 10191–10191. 15 indexed citations

Barak, Yoram, et al.. (2014). Effect of Alfacalcidol on Fatigue in MS Patients: A Randomized, Double-Blind Study (S23.004). Neurology. 82(10_supplement). 3 indexed citations

Comı, Gıancarlo, David Ladkani, Timothy R. Vollmer, et al.. (2014). Mediation of the Effect of Laquinimod on Disability Progression in Relapsing-Remitting Multiple Sclerosis (RRMS) (P3.195). Neurology. 82(10_supplement). 2 indexed citations

Towfic, Fadi, Jason Funt, Kevin Fowler, et al.. (2014). Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. PLoS ONE. 9(1). e83757–e83757. 31 indexed citations

Achiron, Anat, Uri Givon, David Magalashvili, et al.. (2014). Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Multiple Sclerosis Journal. 21(6). 767–775. 60 indexed citations

10.

Weinstein, Vera, et al.. (2009). The glatiramoid class of immunomodulator drugs. Expert Opinion on Pharmacotherapy. 10(4). 657–668. 53 indexed citations

11.

Wolinsky, Jerry S., Tzippy Shochat, Sivan Weiss, & David Ladkani. (2009). Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences. 286(1-2). 92–98. 30 indexed citations

12.

Wolinsky, Jerry S., Ponnada A. Narayana, Paul O’Connor, et al.. (2007). Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial. Annals of Neurology. 61(1). 14–24. 297 indexed citations

13.

Cohen, J. A., Marco Rovaris, Andrew Goodman, et al.. (2007). Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS. Neurology. 68(12). 939–944. 38 indexed citations

14.

Boneschi, Filippo Martinelli, Marco Rovaris, Kenneth P. Johnson, et al.. (2003). Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis Journal. 9(4). 349–355. 64 indexed citations

15.

Wolinsky, J. S., Giancarlo Comi, Massimo Filippi, et al.. (2002). Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology. 59(8). 1284–1286. 40 indexed citations

16.

Rovaris, Marco, Giacomo P. Comi, Maria Pia Sormani, et al.. (2001). Effects of seasons on magnetic resonance imaging–measured disease activity in patients with multiple sclerosis. Annals of Neurology. 49(3). 415–416. 1 indexed citations

17.

Samara, Emil, et al.. (1995). Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharmaceutics & Drug Disposition. 16(3). 201–210. 8 indexed citations

18.

Menczel, J., J. Földes, R. Steinberg, et al.. (1994). Alfacalcidol (Alpha D3) and Calcium in Osteoporosis. Clinical Orthopaedics and Related Research. 300(300). 241???247–241???247. 35 indexed citations

19.

Gozlan, Igal, et al.. (1984). Phase transfer catalysis in N‐alkylation of the pharmaceutical intermediates phenothiazine and 2‐chlorophenothiazine. Journal of Heterocyclic Chemistry. 21(2). 613–614. 10 indexed citations

20.

Rappoport, Zvi & David Ladkani. (1973). Nucleophilic attacks on carbon–carbon double bonds. Part XVIII. Reaction of 2-dicyanomethyleneindane-1,3-dione with anilines in acetonitrile. Journal of the Chemical Society Perkin Transactions 2. 1045–1052. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact